PL421685A1 - New application of 2-isothiocyanate ethylbenzene in therapy of Huntington disease - Google Patents
New application of 2-isothiocyanate ethylbenzene in therapy of Huntington diseaseInfo
- Publication number
- PL421685A1 PL421685A1 PL421685A PL42168517A PL421685A1 PL 421685 A1 PL421685 A1 PL 421685A1 PL 421685 A PL421685 A PL 421685A PL 42168517 A PL42168517 A PL 42168517A PL 421685 A1 PL421685 A1 PL 421685A1
- Authority
- PL
- Poland
- Prior art keywords
- ethylbenzene
- isothiocyanate
- therapy
- new application
- huntington disease
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Przedmiotem zgłoszenia jest nowe zastosowanie 2-izotiocyjanianoetylobenzenu do wytwarzania leku aktywnie hamującego powstawanie agregatów białkowych w komórce, w tym agregatów zmutowanej huntingtyny, zapobiegającego ich akumulacji, oraz aktywującemu proces ich usuwania przez komórkę. Przedmiotem zgłoszenia jest również kompozycja farmaceutyczna, która zawiera substancję aktywną 2-izotiocyjanianoetylobenzen w połączeniu z co najmniej jednym nośnikiem lub rozcieńczalnikiem farmaceutycznym, do zastosowania w leczeniu choroby Huntingtona.The subject of the application is the new use of 2-isothiocyanatoethylbenzene for the production of a drug that actively inhibits the formation of protein aggregates in the cell, including mutated huntingtin aggregates, prevents their accumulation, and activates the process of their removal by the cell. The subject of the application is also a pharmaceutical composition which contains the active substance 2-isothiocyanatoethylbenzene in combination with at least one pharmaceutical carrier or diluent for use in the treatment of Huntington's disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL421685A PL235541B1 (en) | 2017-05-23 | 2017-05-23 | New application of 2-isothiocyanate ethylbenzene in therapy of Huntington disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL421685A PL235541B1 (en) | 2017-05-23 | 2017-05-23 | New application of 2-isothiocyanate ethylbenzene in therapy of Huntington disease |
Publications (2)
Publication Number | Publication Date |
---|---|
PL421685A1 true PL421685A1 (en) | 2018-12-03 |
PL235541B1 PL235541B1 (en) | 2020-09-07 |
Family
ID=64460750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL421685A PL235541B1 (en) | 2017-05-23 | 2017-05-23 | New application of 2-isothiocyanate ethylbenzene in therapy of Huntington disease |
Country Status (1)
Country | Link |
---|---|
PL (1) | PL235541B1 (en) |
-
2017
- 2017-05-23 PL PL421685A patent/PL235541B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL235541B1 (en) | 2020-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019008487A2 (en) | Quinazoline Compound | |
TR201901312T4 (en) | Tetrahydronaphthalene derivatives that inhibit the Mcl-1 protein. | |
MX2019010907A (en) | Farnesoid x receptor agonists and uses thereof. | |
MX2021000071A (en) | Use of pridopidine to improve cognitive function and for treating alzheimer's disease. | |
PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
MX2017016134A (en) | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease. | |
CR20170411A (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE N- (3,5-DIMETOXIFENIL) -N- (1-METHYTILE) -N- [3- (1-METHYL-1H-PIRAZOL-4-IL-QUIN OXALIN-6-IL] ETANO-1 , 2-DIAMINE | |
DOP2015000304A (en) | BROMODOMINIUM CRYSTAL INHIBITORS | |
MX2019007587A (en) | Ophthalmic composition for treatment of dry eye disease. | |
WO2015171610A3 (en) | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease | |
PH12018500762A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
MX2016012574A (en) | Substituted heteroaryl compounds and methods of use. | |
PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
CL2016001918A1 (en) | Heteroaryl amides as protein aggregation inhibitors | |
DOP2019000193A (en) | NEW HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT | |
MX2018012538A (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof. | |
PH12018501362A1 (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
CL2015002835A1 (en) | New pyridine derivatives | |
UY38926A (en) | INHIBITION OF HUMAN INTEGRIN alfa4beta7 | |
BR112018015367A2 (en) | nanofiber oromucosal carriers for therapeutic treatment | |
BR112016030730A8 (en) | compound | |
MY197464A (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
MX2017005522A (en) | Novel treatment of cornea using laminin. | |
UY38352A (en) | INTEGRIN INHIBITORS ALFAVBETA6 | |
BR112017021669A2 (en) | oral pharmaceutical formulations, method for treating diseases and use of said formulations |